PULSE BIOSCIENCES, INC. (PLSE) Stock
4 of the hedge funds AlphaScala tracks reported PLSE in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $17.37M. Company insiders reported 4 open-market buys and 0 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own PLSE?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 627K | $17.37M | +341% |
| Point72 Steve Cohen | 106K | $2.95M | NEW |
| D.E. Shaw David Shaw | 82K | $2.27M | +496% |
| Millennium Management Israel Englander | 23K | $651.3K | -58% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are PULSE BIOSCIENCES, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 1, 26 | Teplitsky Liane Rae | Chief Operating Officer | BUY | 1.0K | $50K |
| Aug 31, 26 | Teplitsky Liane Rae | Chief Operating Officer | BUY | 1.0K | $50K |
| Aug 28, 26 | Teplitsky Liane Rae | Chief Operating Officer | BUY | 1.0K | $50K |
| Aug 26, 26 | Teplitsky Liane Rae | Chief Operating Officer | BUY | 1.0K | $50K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →PLSE price chart
Powered by TradingViewWhat does PULSE BIOSCIENCES, INC. do?
Pulse Biosciences, Inc. is a bioelectric medicine company specializing in the development of novel Nanosecond Pulsed Field Ablation (nsPFA) platforms. Its primary focus centers on the patented nPulse technology, which enables precise, non-thermal ablation of soft tissues for applications in dermatology, cardiology, and surgical procedures. Key products include the CellFX System for treating benign skin lesions, the CellFX nsPFA Percutaneous Electrode for soft tissue ablation, the CellFX nsPFA Cardiac Clamp for surgical atrial fibrillation treatment, and the CellFX nsPFA 360° Cardiac Catheter for circumferential cardiac ablation. The company also offers the CellFX Console, a tunable, software-enabled platform supporting physician workflows. Pulse Biosciences, Inc. targets high-impact healthcare areas such as restoring normal cardiac rhythm in atrial fibrillation patients and ablating benign thyroid nodules and tumors. Founded in 2014 and headquartered in Miami, Florida, it plays a pivotal role in advancing minimally invasive, bioelectric therapies within the medical instruments and supplies sector.